Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome

Paula J. Hurley, Luigi Marchionni, Brian W. Simons, Ashley E. Ross, Sarah B. Peskoe, Rebecca M. Miller, Nicholas Erho, Ismael A. Vergara, Mercedeh Ghadessi, Zhenhua Huang, Bora Gurel, Ben Ho Park, Elai Davicioni, Robert B. Jenkins, Elizabeth A. Platz, David M. Berman, Edward M. Schaeffer

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Prostate cancer is the second leading cause of cancer death among United States men. However, disease aggressiveness is varied, with low-grade disease often being indolent and high-grade cancer accounting for the greatest density of deaths. Outcomes are also disparate among men with high-grade prostate cancer, with upwards of 65% having disease recurrence even after primary treatment. Identification of men at risk for recurrence and elucidation of the molecular processes that drive their disease is paramount, as these men are the most likely to benefit from multimodal therapy. We previously showed that androgen-induced expression profiles in prostate development are reactivated in aggressive prostate cancers. Herein, we report the down-regulation of one such gene, Sparcl1, a secreted protein, acidic and rich in cysteine (SPARC) family matricellular protein, during invasive phases of prostate development and regeneration. We further demonstrate a parallel process in prostate cancer, with decreased expression of SPARCL1 in high-grade/metastatic prostate cancer. Mechanistically, we demonstrate that SPARCL1 loss increases the migratory and invasive properties of prostate cancer cells through Ras homolog gene family, member C (RHOC), a known mediator of metastatic progression. By using models incorporating clinicopathologic parameters to predict prostate cancer recurrence after treatment, we show that SPARCL1 loss is a significant, independent prognostic marker of disease progression. Thus, SPARCL1 is a potent regulator of cell migration/invasion and its loss is independently associated with prostate cancer recurrence.

Original languageEnglish (US)
Pages (from-to)14977-14982
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number37
DOIs
StatePublished - Sep 11 2012

Keywords

  • Extracellular matrix
  • Hevin
  • Synaptic cleft 1
  • Urogenital sinus

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome'. Together they form a unique fingerprint.

  • Cite this

    Hurley, P. J., Marchionni, L., Simons, B. W., Ross, A. E., Peskoe, S. B., Miller, R. M., Erho, N., Vergara, I. A., Ghadessi, M., Huang, Z., Gurel, B., Park, B. H., Davicioni, E., Jenkins, R. B., Platz, E. A., Berman, D. M., & Schaeffer, E. M. (2012). Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 109(37), 14977-14982. https://doi.org/10.1073/pnas.1203525109